The Clinical Research Of Intraoperative Interstitial Chemotherapy With Fluorouracil Sustained-release Implants In Breast Cancer

Objective:To investigate the safety and clinical efficacy of intraoperative interstitialchemotherapy with fluorouracil sustained-release implants in breast cancer,andexplore a new way to prevent the recurrence and metastasis of breast cancer.Methods:There were111breast cancer patients in our hospital during2008-2012whowere divided into implanting group(n=51) and control group(n=60) randomly.Thefluorouracil sustained-release implants had been implanted in the implantinggroup.Postoperative incision、toxic and side-effects、tumor recurrence and metastasis、2-year survival rate were observed between the two groups.Results:There were no significant differences in the incidence of incision infection、subcutaneous hydrops、skin flap necrosis、limb edema、lymphatic leakage between thetwo group(P>0.05).The implanting group have no drug side effects such as nausea、vomiting、hair loss.Levels of red blood cells、white blood cells、 creatinine andalanine aminotransferase between the two groups had no statistical significance (P>0.05). Compared with control group,fluorouracil implant significantly decreasedrecurrence and metastasis rate (3.92%vs25%,P=0.002).Follow-up with2yearslater,there were no death cases comparing the two groups. The metastasis of axillarylymph node（HR=0.208，P=0.015） and primary tumor T3-4(HR=0.306，P=0.018)were risk factors for poor relapse-free survival.Conclusion:1.Intraoperative interstitial chemotherapy with fluorouracil sustained-releaseimplants in breast cancer patients is safe and effective.It might become a newpromising method to prevent the postoperative recurrence and metastasis of breastcancer, and improve the survival rate in the patients of breast cancer.2.Intraoperative interstitial chemotherapy with fluorouracil sustained-releaseimplants might be an effective way to improve the survival for those patients who have the metastasis of axillary lymph node and primary tumor (T3-4).